scholarly journals Venlafaxine extended-release capsules in panic disorder

2005 ◽  
Vol 187 (4) ◽  
pp. 352-359 ◽  
Author(s):  
Jacques Bradwejn ◽  
Antti Ahokas ◽  
Dan J. Stein ◽  
Eliseo Salinas ◽  
Gerard Emilien ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Panic Disorder ◽  
Extended Release ◽  
Term Treatment ◽  
Panic Attacks ◽  
Double Blind Study ◽  
Short Term Treatment ◽  
Double Blind ◽  
Proven Efficacy ◽  
To Receive

BackgroundVenlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.AimsTo evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.MethodAdult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75–225 mg/day) or placebo for up to 10 weeks in a double-blind study.ResultsVenlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the finalon-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.ConclusionsVenlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.

scholarly journals Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder

2001 ◽  
Vol 179 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Christer Allgulander ◽  
David Hackett ◽  
Eliseo Salinas
Keyword(s):  
Anxiety Disorder ◽  
Extended Release ◽  
Term Treatment ◽  
Double Blind Study ◽  
Generalised Anxiety Disorder ◽  
Double Blind ◽  
Treatment Groups ◽  
Long Term Treatment ◽  
Higher Doses

BackgroundGeneralised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.AimsTo assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.MethodA total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.ResultsAll doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.ConclusionsVenlafaxine ER is an effective and safe treatment for GAD for up to 6 months.

A Multicenter, Randomized, Double-Blind Study Comparing a Daily Bedtime Administration of Famotidine and Ranitidine in Short-Term Treatment of Active Duodenal Ulcer

Digestion ◽  
1989 ◽  
Vol 42 (2) ◽  
pp. 79-85 ◽  
Author(s):  
R. Alcalá-Santaella ◽  
J. Guardia ◽  
J. Pajares ◽  
J. Piqué ◽  
L. Pita ◽  
...  
Keyword(s):  
Duodenal Ulcer ◽  
Term Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Short Term ◽  
Short Term Treatment ◽  
Double Blind

New treatments for panic

1998 ◽  
Vol 13 (S2) ◽  
pp. 75s-81s ◽  
Author(s):  
JC Ballenger
Keyword(s):  
Panic Disorder ◽  
Adverse Events ◽  
Dropout Rate ◽  
Prolonged Treatment ◽  
Double Blind Study ◽  
Onset Of Action ◽  
Double Blind ◽  
New Treatments ◽  
To Receive

SummaryPanic disorder is a chronic condition for many patients and can be socially, emotionally and occupationally disabling. Until recently, clomipramine and alprazolam were the only drugs approved for its treatment. While widely used in the US and Europe, both belong to drug classes (tricyclics and benzodiazepines) with well-recognised side effects that can be problematic and thus limit their use. Recently, paroxetine became the first selective serotonin reuptake inhibitor to receive approval and licensing for panic disorder.The short- and long-term efficacy and tolerability of paroxetine in panic disorder has been established in clinical trials of almost 1,000 patients meeting Diagnostic and Statistical Manual (DSM)-IIIR criteria for panic disorder, with or without agoraphobia. In a 12-week double-blind study of 120 panic patients receiving standardised cognitive therapy, paroxetine was significantly more effective than placebo in reducing panic attack frequency. In a 12-week placebo-controlled comparison in 367 panic patients, paroxetine was at least as effective as clomipramine and better tolerated. There was also some evidence that paroxetine had an earlier onset of action than clomipramine.A 9-month extension of the placebo-controlled comparison with clomipramine showed that the efficacy of paroxetine and clomipramine is maintained when treatment is continued into the longer term. In a relapse prevention study, 105 responders to 3 months' treatment with paroxetine or placebo were re-randomised, either to continue existing treatment or to receive placebo for 3 months. Only 5% of patients who continued to take paroxetine experienced a relapse compared with 30% of those who switched to placebo (P = 0.002). Paroxetine was generally well tolerated. In the short-term trials, the frequency of withdrawals due to adverse events (7.3%) was lower than that for placebo (11.4%) or clomipramine (14.9%). In the longer term, the dropout rate due to adverse events increased in the clomipramine group (19.0%) but was unchanged in the paroxetine group (7.4%). Since most patients with panic disorder will require prolonged treatment, the long-term tolerability of paroxetine and its lack of potential for dependence are important advantages that will encourage good compliance with treatment and improve the quality of life of patients.

scholarly journals Diurnal panic attacks with and without nocturnal panic attacks: are there some phenomenological differences?

2005 ◽  
Vol 27 (3) ◽  
pp. 216-221 ◽  
Author(s):  
Fabiana L Lopes ◽  
Antonio E Nardi ◽  
Isabella Nascimento ◽  
Alexandre M Valença ◽  
Marco A Mezzasalma ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Attention Deficit Disorder ◽  
Panic Attack ◽  
Age At Onset ◽  
Term Treatment ◽  
Panic Attacks ◽  
Short Term ◽  
Short Term Treatment ◽  
Term Outcome ◽  
Cross Sectional

OBJECTIVE: To compare nocturnal and diurnal panic attacks in a cross-sectional study and in a longitudinal prospective short-term follow-up. METHODS: We selected 57 panic disorder (PD) subjects (DSM-IV) and rated them with the Panic Disorder Severity Scale (PDSS) at baseline and after 30 days of treatment with nortriptyline, and with the Eysenck Personality Inventory and the Brown Attention Deficit Disorder (ADD) Scale at baseline. RESULTS: The sample was divided into a nocturnal and diurnal panic attack (NDPA) group - 57.9% (n = 33) - and a diurnal panic attack (DPA) group - 42.1% (n = 24). The groups showed a similar mean age at onset of PD and a pattern of prominent respiratory symptoms. The PDSS did not differ between the groups following short-term treatment (p = 0.451). There were also neither significant differences in Neuroticism (p = 0.094) and Extroversion (p = 0.269) nor in the Brown ADD Scale (p = 0.527). CONCLUSION: In our study, patients with both nocturnal and diurnal panic attacks showed similar features in their phenomenology and short-term outcome when compared to pure diurnal panic attacks patients.

Comparison of Symptom-free Days in Generalized Anxiety Disorder Following Treatment with Pregabalin or Venlafaxine-XR

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
D.L. Hoffman ◽  
M.A. Mychaskiw ◽  
E.M. Dukes ◽  
W.E. Dodge ◽  
A. Joshi
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Term Treatment ◽  
Generalized Anxiety ◽  
Short Term Treatment ◽  
Double Blind ◽  
Reported Study ◽  
Dsm Iv ◽  
Post Hoc ◽  
Flexible Dose

Aims:To estimate the clinical benefit of pregabalin and venlafaxine-XR for the short-term treatment of generalized anxiety disorder (GAD) using the metric of symptom-free days (SFDs).Methods:A post-hoc analysis of a clinical trial in which adults who met DSM-IV criteria for GAD, with a HAM-A total score ≥ 20, were randomized to 8-weeks of double-blind, flexible-dose treatment with pregabalin (300-600 mg/d), venlafaxine-XR (75-225 mg/d) or placebo. SFDs were estimated for each one-week period based on weekly HAM-A scores using a published algorithm. Differences were analyzed using pairwise comparisons from a GLM adjusting for baseline HAM-A and sites.Results:The sample consisted of 121 patients on pregabalin (female, 64%; mean age, 39.5 years; LS mean ± SE baseline HAM-A, 27.6 ± 0.5), 125 patients on venlafaxine-XR (female, 58%; mean age, 42.6 years; baseline HAM-A, 27.5 ± 0.5), and 128 patients on placebo (female, 61%; mean age, 40.2 years; baseline HAM-A, 26.8 ± 0.5). At endpoint, LS mean (± SE) number of SFDs was significantly higher for pregabalin (20.6 ± 1.4) compared with both venlafaxine-XR (16.5 ± 1.4; p=0.018) and placebo (15.5 ± 1.3; p=0.004). Values remained significant after adjusting for multiple comparisions (p=0.0447 and p=0.0107, respectively).Conclusion:Treatment with pregabalin resulted in more SFDs compared with venlafaxine-XR and placebo. The lack of difference in SFDs for groups treated with venlafaxine-XR compared to placebo contrasts with a previously reported study. Further studies are warranted to explore the application of the SFD metric.

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

2006 ◽  
Vol 24 (1) ◽  
pp. 1-14 ◽  
Author(s):  
Mark H. Pollack ◽  
Ulla Lepola ◽  
Hannu Koponen ◽  
Naomi M. Simon ◽  
John J. Worthington ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Extended Release ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

Functional and Quality of Life Impairment in Generalized Anxiety Disorder: Effect of Short-term Treatment with Pregabalin and Venlafaxine-XR

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
M.A. Mychaskiw ◽  
J.M. Alvir ◽  
D.L. Hoffman ◽  
B.K. Herman ◽  
A. Joshi
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Change Score ◽  
Term Treatment ◽  
Similar Proportion ◽  
Generalized Anxiety ◽  
Short Term Treatment ◽  
Double Blind

Aims:To determine the incidence and clinical correlates of functional and quality of life (QoL) impairment in patients with generalized anxiety disorder (GAD), and to evaluate the efficacy of pregabalin and venlafaxine-XR in improving functional outcomes.Methods:A double-blind trial in adults who met DSM-IV criteria for GAD, with a HAM-A total score ≥20, randomized to 8-weeks of flexible-dose treatment with pregabalin (300-600 mg/d, N=121), venlafaxine-XR(75-225 mg/d, N=125), or placebo (N=128). Anxiety-related impairment in QoL was evaluated using the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q) and impairment in functioning using the Sheehan Disability Scale (SDS).Results:At baseline, a similar proportion of patients in the 3 treatment groups met criteria for impairment on the Q-LES-Q (70.1%-77.6%) and SDS (74.1%-82.7%). For all groups combined, baseline impairment was more highly correlated with psychic than somatic anxiety on both the Q-LES-Q and SDS (Spearman r-values, -0.32 vs. -0.28 and 0.27 vs. 0.14,respectively). On the SDS but not on the Q-LES-Q, significantly more subjects in the pregabalin (67.2%) and venlafaxine-XR (59.5%) groups had improvement into the normative range compared with placebo (42.9%; p< 0.05) at endpoint. The mean HAM-A change score (all subjects) was significantly greater among patients whose Q-LES-Q returned to normal (“remitters” vs. non-remitters: -19.3 vs. -11.9; p< 0.05).Conclusion:At baseline, approximately 75% of GAD patients reported moderate-to-severe impairment in QoL and functioning which was modestly correlated with severity of GAD symptomatology. Pregabalin produced improvement in QoL and functioning that was correlated with reduction in anxiety symptom severity.

Sign in / Sign up

Export Citation Format

Share Document